See more : New York Mortgage Trust, Inc. (NYMTL) Income Statement Analysis – Financial Results
Complete financial analysis of Nxera Pharma Co., Ltd. (4565.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nxera Pharma Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- V Group, Inc. (VGID) Income Statement Analysis – Financial Results
- Elme Communities (ELME) Income Statement Analysis – Financial Results
- Kalyani Forge Limited (KALYANIFRG.NS) Income Statement Analysis – Financial Results
- Midas Minerals Limited (MM1.AX) Income Statement Analysis – Financial Results
- cBrain A/S (CBRAIN.CO) Income Statement Analysis – Financial Results
Nxera Pharma Co., Ltd. (4565.T)
About Nxera Pharma Co., Ltd.
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company's development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.77B | 15.57B | 17.71B | 8.84B | 9.73B | 3.83B | 6.96B | 18.90B | 8.15B | 3.67B | 2.07B | 1.96B | 862.41M | 716.57M | 919.68M | 152.91M | 709.12M | 739.78M | 415.50M | 244.40M |
| Cost of Revenue | 3.10B | 926.00M | 933.00M | 761.00M | 851.00M | 1.82B | 0.00 | 923.00M | 4.00M | 68.33M | 251.40M | 325.75M | 253.92M | 50.64M | 127.70M | 121.55M | 122.33M | 490.51M | 364.76M | 13.05M |
| Gross Profit | 9.66B | 14.64B | 16.78B | 8.08B | 8.88B | 2.01B | 6.96B | 17.98B | 8.15B | 3.60B | 1.82B | 1.63B | 608.49M | 665.93M | 791.98M | 31.36M | 586.79M | 249.27M | 50.74M | 231.35M |
| Gross Profit Ratio | 75.70% | 94.05% | 94.73% | 91.39% | 91.25% | 52.54% | 100.00% | 95.12% | 99.95% | 98.14% | 87.85% | 83.37% | 70.56% | 92.93% | 86.11% | 20.51% | 82.75% | 33.69% | 12.21% | 94.66% |
| Research & Development | 10.08B | 7.45B | 5.93B | 3.79B | 4.29B | 7.18B | 4.94B | 3.22B | 3.92B | 557.78M | 305.03M | 385.00M | 227.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.97B | 4.38B | 3.94B | 3.44B | 3.61B | 0.00 | 4.48B | 3.57B | 3.29B | 1.95B | 882.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.46B | 1.98B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.97B | 4.38B | 3.94B | 3.44B | 3.61B | 2.23B | 4.48B | 3.57B | 3.29B | 1.95B | 882.14M | 613.00M | 756.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.46B | 1.98B |
| Other Expenses | -850.00M | -624.00M | 3.13B | -75.00M | 585.00M | 0.00 | 0.00 | -279.00M | -138.00M | -9.93M | -125.13M | 62.67M | 26.34M | 885.00K | 835.00K | 1.74M | -13.62M | 27.27M | -846.00K | -2.40M |
| Operating Expenses | 19.19B | 11.21B | 13.00B | 7.15B | 8.49B | 9.41B | 9.25B | 6.51B | 7.07B | 2.49B | 1.06B | 2.59B | 2.57B | 2.54B | 2.65B | 3.70B | 6.86B | 6.90B | 4.46B | 1.98B |
| Cost & Expenses | 22.29B | 12.13B | 13.94B | 7.91B | 9.34B | 11.23B | 9.25B | 6.51B | 7.08B | 2.56B | 1.31B | 2.91B | 2.83B | 2.59B | 2.77B | 3.82B | 6.98B | 7.39B | 4.82B | 2.00B |
| Interest Income | 1.34B | 663.00M | 199.00M | 1.63B | 824.00M | 0.00 | 104.00M | 1.52B | 4.00M | 405.14M | 30.05M | 1.22M | 337.00K | 1.03M | 4.07M | 12.58M | 93.39M | 189.91M | 147.27M | 1.50M |
| Interest Expense | 2.50B | 756.00M | 3.80B | 578.00M | 493.00M | 0.00 | 1.24B | 479.00M | 4.38B | 147.35M | 48.60M | 0.00 | 0.00 | 0.00 | 0.00 | 243.43M | 1.07B | 0.00 | 0.00 | 89.76M |
| Depreciation & Amortization | 2.48B | 1.35B | 1.28B | 1.35B | 1.49B | 1.37B | 1.03B | 923.00M | 926.00M | 33.19M | 20.35M | 1.61B | 1.61B | 1.60B | 1.60B | 1.61B | 1.64B | 1.63B | 959.69M | 8.69M |
| EBITDA | -5.71B | 5.02B | 8.19B | 2.20B | 2.45B | -6.41B | -1.44B | 13.05B | 1.86B | 1.46B | 758.20M | 1.01B | -355.00M | -271.35M | -253.55M | -2.05B | -4.63B | -5.02B | -3.44B | -1.74B |
| EBITDA Ratio | -44.70% | 32.21% | 29.93% | 40.15% | 25.87% | -157.49% | -20.63% | 77.26% | 24.61% | 42.14% | 38.98% | 31.94% | -40.96% | -50.60% | -29.17% | -1,425.70% | -573.83% | -678.07% | -827.28% | -703.09% |
| Operating Income | -9.53B | 3.67B | 4.02B | 2.20B | 1.03B | -7.40B | -2.29B | 12.39B | 1.08B | 1.11B | 756.39M | -953.43M | -1.96B | -1.88B | -1.85B | -3.67B | -6.27B | -6.65B | -4.41B | -1.75B |
| Operating Income Ratio | -74.62% | 23.57% | 22.72% | 24.88% | 10.56% | -193.28% | -32.94% | 65.55% | 13.19% | 30.20% | 36.54% | -48.67% | -227.57% | -261.83% | -201.67% | -2,398.44% | -884.14% | -899.05% | -1,060.57% | -717.43% |
| Total Other Income/Expenses | -1.15B | -2.36B | -3.34B | -578.00M | -435.00M | -2.01B | -1.41B | 372.00M | -4.37B | 258.00M | -18.55M | 102.63M | 11.35M | 4.51M | 87.68M | -370.53M | -509.39M | 127.50M | 91.04M | -63.39M |
| Income Before Tax | -10.68B | 1.08B | 433.00M | 1.62B | 534.00M | -9.64B | -3.70B | 12.48B | -3.30B | 1.37B | 737.85M | -757.32M | -1.95B | -1.87B | -1.77B | -4.04B | -6.78B | -6.52B | -4.32B | -1.82B |
| Income Before Tax Ratio | -83.66% | 6.92% | 2.44% | 18.34% | 5.49% | -251.62% | -53.23% | 66.04% | -40.45% | 37.22% | 35.65% | -38.66% | -226.26% | -261.20% | -192.13% | -2,640.81% | -955.98% | -881.81% | -1,038.66% | -743.37% |
| Income Tax Expense | -3.49B | 696.00M | -584.00M | 143.00M | -898.00M | -1.69B | -1.05B | 2.84B | -1.75B | 804.11M | -788.33M | 7.76M | 3.11M | 215.00K | 2.16M | -99.44M | -275.46M | -283.92M | -139.94M | 3.61M |
| Net Income | -7.19B | 382.00M | 1.02B | 1.48B | 1.43B | -7.95B | -2.65B | 9.64B | -1.55B | 562.52M | 1.53B | -646.86M | -1.95B | -1.87B | -1.77B | -3.94B | -6.50B | -6.24B | -4.18B | -1.82B |
| Net Income Ratio | -56.34% | 2.45% | 5.74% | 16.73% | 14.72% | -207.54% | -38.16% | 50.99% | -18.98% | 15.32% | 73.73% | -33.02% | -226.62% | -261.23% | -192.37% | -2,575.78% | -917.14% | -843.43% | -1,004.98% | -744.84% |
| EPS | -87.17 | 4.67 | 12.53 | 18.78 | 18.69 | -104.29 | -37.55 | 137.79 | -25.28 | 9.38 | 31.66 | -13.63 | -41.29 | -39.67 | -37.51 | -83.52 | -138.14 | -154.79 | -125.50 | -80.34 |
| EPS Diluted | -87.17 | 4.63 | 12.40 | 18.61 | 18.48 | -104.24 | -37.55 | 137.31 | -25.27 | 9.29 | 31.22 | -13.50 | -41.29 | -39.67 | -37.51 | -83.52 | -138.14 | -154.79 | -125.50 | -80.34 |
| Weighted Avg Shares Out | 82.52M | 81.79M | 81.19M | 78.74M | 76.62M | 76.21M | 70.69M | 67.57M | 61.20M | 55.04M | 48.20M | 47.44M | 47.34M | 47.18M | 47.16M | 47.16M | 47.08M | 40.31M | 33.27M | 22.66M |
| Weighted Avg Shares Out (Dil) | 82.52M | 82.59M | 82.01M | 79.49M | 77.48M | 76.24M | 70.69M | 67.81M | 61.21M | 55.59M | 48.88M | 47.92M | 47.34M | 47.18M | 47.16M | 47.16M | 47.08M | 40.31M | 33.27M | 22.66M |
Source: https://incomestatements.info
Category: Stock Reports